A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.
Epistemonikos ID: 24fe8fb9693b96e03b0835e170073d1a1e0f6868
First added on: May 09, 2024